



EVO ICL Expands Vision Correction Options for Patients with High Myopia at Brusco Vision

June 10, 2025

FALLS CHURCH, VA - June 10, 2025 - PRESSADVANTAGE -

Patients with high or ultra-high myopia who have been told they are not candidates for LASIK may now have a new and reliable option for clear vision. Brusco Vision, a premier vision correction center led by board-certified ophthalmologist Dr. Michael Brusco, is offering EVO ICL as a safe, effective solution for patients whose prescriptions fall outside the LASIK treatment range. With the demand for alternative vision correction procedures on the rise, this FDA-approved implantable lens is transforming outcomes for individuals with prescriptions as high as -20 diopters.

Myopia, or nearsightedness, affects millions of people in the United States. For patients with severe myopia—often defined as greater than -6.00 diopters—the number of treatment options has historically been limited. Many are told they do not qualify for LASIK due to high prescriptions, thin corneas, or dry eye syndrome. EVO ICL, or Implantable Collamer Lens, provides a new path forward. Unlike laser vision correction procedures, EVO ICL does not require the removal of any corneal tissue. The lens is placed inside the eye, behind the iris and in front of the natural lens, offering a long-term vision correction solution without altering the natural shape of the cornea.

Brusco Vision is seeing exceptional outcomes with EVO ICL for patients who had previously exhausted other options. According to a study published in the National Library of Medicine, 100% of patients who had correctable vision to 20/20 before surgery achieved 20/20 or better without glasses just one month after undergoing EVO ICL. Long-term follow-up has also shown that 47.5% of patients with prescriptions higher than -12.00 diopters achieved outcomes within ± 1.00 diopters of the intended target five years post-surgery. These statistics highlight the procedure's accuracy, safety, and consistency—factors that have contributed to its growing adoption by leading ophthalmologists.

The safety profile of EVO ICL is one of its most compelling features. The lens is made from a biocompatible material called Collamer, which works in harmony with the natural structures of the human eye. Unlike other refractive procedures that involve permanent changes to the cornea, EVO ICL is completely reversible. If necessary, the lens can be removed or replaced, offering patients flexibility and peace of mind. With a satisfaction rate of 99.4%, the procedure is well-tolerated and associated with a low rate of complications. Studies show no significant long-term impact on corneal endothelial cell density or intraocular pressure, and fewer than 6% of patients required secondary enhancements—primarily in cases involving extreme prescriptions above -18.00 diopters.

Dr. Michael Brusco is a recognized leader in advanced vision correction and performs every EVO ICL procedure himself at Brusco Vision. His extensive background in ophthalmology and refractive surgery, combined with the latest diagnostic tools and imaging technology, ensures a high level of precision and individualized care. Every patient undergoes a comprehensive consultation, including corneal topography and anterior chamber measurements, to determine candidacy and select the ideal lens size and type. This level of customization has been key in delivering consistently high patient outcomes, particularly for those with complex visual profiles.

The ideal candidates for EVO ICL include adults with stable prescriptions typically ranging from -3.00 to -20.00 diopters. Many have been previously advised against LASIK due to severe nearsightedness, dry eye issues, or insufficient corneal thickness. EVO ICL is also an option for some individuals with mild keratoconus or early signs of hyperopia, provided their ocular anatomy meets certain criteria. Patients who value the reversibility of the lens and want to preserve their corneal structure often find this procedure particularly appealing. For those hesitant about permanent alterations to the eye, EVO ICL offers a highly effective and less invasive alternative.

In addition to its strong performance metrics, EVO ICL also improves quality of life for patients who have struggled with glasses or contact lenses for years. Many report greater visual clarity, reduced dependence on corrective lenses, and improved comfort during daily tasks, work, and recreation. Unlike glasses, which can distort peripheral vision, or contact lenses, which require constant care, EVO ICL offers stable, maintenance-free correction. The procedure is especially beneficial for patients with active lifestyles or

professional demands that make traditional vision aids cumbersome.

FDA approval for EVO ICL underscores the rigorous safety and efficacy standards the technology has met. The lens is currently approved by the United States Food and Drug Administration for use in patients with myopia, including those with high or ultra-high prescriptions. With years of clinical data supporting its performance, the EVO ICL has earned recognition from ophthalmologists and optometrists as a trusted solution for difficult cases. At Brusco Vision, the technology plays a central role in the practice's commitment to providing comprehensive, patient-focused refractive surgery.

Brusco Vision continues to attract patients from across the region who are seeking answers beyond the limitations of LASIK. Dr. Brusco and his team are committed to educating patients on their full range of vision correction options. During consultations, patients are walked through every step of the EVO ICL process—from diagnosis and measurements to surgical planning and post-op care. This thorough approach is designed to empower patients with knowledge and build confidence in their decision. For many, the ability to finally access a safe, effective vision correction solution marks a turning point in their quality of life.

The field of ophthalmology is rapidly evolving, and EVO ICL represents a significant advancement in the treatment of high myopia. As awareness grows, more patients are discovering that being told "you're not a candidate for LASIK" doesn't mean the end of the road. At Brusco Vision, EVO ICL is helping individuals with severe refractive error reclaim their vision and gain lasting independence from glasses and contacts. Dr. Brusco encourages those who were previously turned away from laser vision correction to revisit their options and learn more about this innovative lens-based procedure.

Members of the media interested in interviewing Dr. Michael Brusco or learning more about EVO ICL for high myopia can contact the Brusco Vision media team for additional data, patient stories, and expert commentary. Patients seeking personalized evaluations are encouraged to schedule a consultation directly through the Brusco Vision website.

###

For more information about Brusco Vision, contact the company here: Brusco Vision Michael Brusco, MD (571) 755-2020 info@bruscovision.com Brusco Vision 3120 Fairview Park Dr Ste 100 Falls Church, VA 22042

Brusco Vision

Brusco Vision is a next-generation vision center providing LASIK and refractive vision correction procedures to Washington DC, DMV, and North Virginia residents. LASIK, PRK, EVO ICL, SMILE, and Custom Lens Replacement

(RLE).

Website: <https://www.bruscovision.com/>

Email: info@bruscovision.com

Phone: (571) 755-2020



Powered by [PressAdvantage.com](https://www.PressAdvantage.com)